This trial is testing a new treatment for salivary gland cancer that has spread or come back and is not able to be treated with surgery or radiation.
1 Primary · 5 Secondary · Reporting Duration: 35 months
Experimental Treatment
20 Total Participants · 1 Treatment Group
Primary Treatment: Pembrolizumab · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: